AMRN
Amarin Corporation plc
AMRN has slightly lower modeled downside risk, despite its lower overall score.
NVO
Novo Nordisk A/S
NVO has a slight edge over AMRN overall, supported by stronger modeled upside.
AMRN Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Strong | |
| Unavailable |
AMRN's cash flow is currently strong, but its revenue and profitability are under pressure. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
AMRN PE Valuation
AMRN has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
AMRN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| Weakening | |
| Limited | |
| High |
Analysts expect AMRN's losses to grow, with revenue declining.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
NVO has the edge over AMRN on the outlook, with more favorable earnings and revenue expectations.
AMRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.05 | +$3.20 |
| Q2 2026 | -$0.07 | +$4.36 |
| Q1 2026 | -$0.08 | +$4.32 |
| Q4 2025 | -$0.85 | +$3.15 |
| Q3 2025 | -$3.25 | -$1.25 |
| Q2 2025 | -$4.43 | -$2.63 |
| Q1 2025 | -$4.40 | -$1.80 |
| Q4 2024 | -$4.00 | -$1.00 |
AMRN is still losing money, but far less than before: $0.05 per share over the past year, against $5.36 at its worst in late 2022.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over AMRN on earnings quality, reporting a profit while its opponent remains loss making.
AMRN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $39.6M | -20% |
| Q2 2026 | $42.2M | -42% |
| Q1 2026 | $45.1M | +7.4% |
| Q4 2025 | $49.2M | -21% |
| Q3 2025 | $49.7M | +17% |
| Q2 2025 | $72.7M | +7.8% |
| Q1 2025 | $42M | -26% |
| Q4 2024 | $62.3M | -17% |
AMRN's revenue has slid since its 2020 peak: $40M last quarter, down 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -6% | +16 points |
| Q2 2026 | -28% | -6.5 points |
| Q1 2026 | -25% | +15 points |
| Q4 2025 | -13% | +72 points |
| Q3 2025 | -22% | +37 points |
| Q2 2025 | -22% | -21 points |
| Q1 2025 | -40% | -16 points |
| Q4 2024 | -84% | -78 points |
AMRN's operating margin was −6% last quarter, up 16 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over AMRN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over AMRN on profitability, with a higher operating margin.
AMRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $9.2M | +$21.9M |
| Q2 2026 | $6.6M | -60% |
| Q1 2026 | $6.4M | +$18.8M |
| Q4 2025 | $15.3M | +$28.6M |
| Q3 2025 | -$12.7M | -$10.3M |
| Q2 2025 | $16.6M | +$19.4M |
| Q1 2025 | -$12.5M | +$142K |
| Q4 2024 | -$13.3M | -$12.7M |
AMRN's free cash flow has turned positive after two years mostly in the red: $37M over the past year.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
AMRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +11.4M shares |
| 1 year | +3% | +12.3M shares |
| 3 years | +1995% | +407M shares |
| 5 years | +2058% | +408M shares |
| Available history | +2398% | +411M shares |
AMRN has 428M diluted shares, up 3% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over AMRN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
AMRN Net Leverage
AMRN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
AMRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.1 | Neutral |
| Stochastic | 13.7 | Oversold |
AMRN's weekly RSI is 36 (neutral) and its Stochastic is 14 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
AMRN PE vs Healthcare Sector
AMRN has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
AMRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.0 | 2.8% below |
| 20 week MA | $13.3 | 12% below |
| 50 week MA | $14.2 | 18% below |
| 100 week MA | $13.7 | 15% below |
| 200 week MA | $16.8 | 31% below |
AMRN is in a downtrend: it's below all five of its weekly moving averages, and 31% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over AMRN on trend strength, trading above more of its moving averages.
AMRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $431.0 | $100.2 | -77% |
| 2021 | $100.2 | $70.2 | -30% |
| 2022 | $70.2 | $25.0 | -64% |
| 2023 | $25.0 | $17.4 | -30% |
| 2024 | $17.4 | $8.96 | -49% |
| 2025 | $8.96 | $14.1 | +58% |
| 2026 YTD | $14.1 | $11.7 | -17% |
AMRN has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.